Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
31.79
+0.20 (0.63%)
At close: Jan 22, 2026, 4:00 PM EST
32.42
+0.63 (1.98%)
After-hours: Jan 22, 2026, 5:05 PM EST
Upstream Bio Revenue
Upstream Bio had revenue of $683.00K in the quarter ending September 30, 2025, with 12.52% growth. This brings the company's revenue in the last twelve months to $2.80M, up 26.82% year-over-year. In the year 2024, Upstream Bio had annual revenue of $2.37M, down -0.42%.
Revenue (ttm)
$2.80M
Revenue Growth
+26.82%
P/S Ratio
615.78
Revenue / Employee
$53,827
Employees
52
Market Cap
1.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
| Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
| Dec 31, 2022 | 1.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 17 days ago - Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study - Seeking Alpha
- 2 months ago - Upstream Bio to Participate in Upcoming December Investor Conferences - GlobeNewsWire
- 2 months ago - Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 2 months ago - Upstream Bio to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 4 months ago - Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - GlobeNewsWire
- 4 months ago - Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 4 months ago - Upstream Bio, Inc. - Special Call - Seeking Alpha